Employees: 33
Size Avalo Therapeutics (AVTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 2854th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.70 on 18 Nov 2026.
Performance Over six months the shares fell 58.9%, against -17.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue fell 69.3% over the last twelve months (peer median -8.0%); the operating margin is -161,961.0% (peer median -7.8%).
Capital Return on invested capital runs 174.7 points below its cost of capital (8.9% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $59,000 | $59,000 | $441,000 | $1.92M | $18.1M |
| Revenue growth | — | -87% | -77% | -89% | — |
| Gross profit | -$9,000 | -$285,000 | $638,000 | $640,000 | $14.6M |
| EBITDA | -$95.5M | -$72.6M | -$40.7M | -$23.3M | -$37.3M |
| Net income | -$88.7M | -$78.3M | -$35.1M | -$31.5M | -$41.7M |
| Free cash flow | -$63.5M | -$51.5M | -$49.1M | -$30.8M | -$26.8M |
| Capital expenditure | $0 | $0 | $0 | $158,000 | $95,000 |
| Total debt | $2.15M | $2.43M | $2.92M | $3.90M | $23.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -45.8% | -11.2% | lowest of 20 |
| 6-month return | -58.9% | -17.8% | 2nd lowest of 19 |
| Distance from 52-week high | -72.4% | -38.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | -69.3% | -8.0% | lowest of 18 |
| Operating margin | -161,961.0% | -7.8% | lowest of 19 |
| ROIC minus cost of capital | -174.7 pp | -2.5 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $407M | -15% | -16% | 7% | 1.7× | -3.2% | +11.2% |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |